STAT

Opinion: Noncommunicable diseases among women: a ‘slow motion disaster’

"Women are not dying of diseases we can't treat. They are dying because societies have yet to make the decision that their lives are worth saving." Our societies need to…
A Nepali health worker checks the blood pressure of a pregnant woman at a health center in the Ramechhap district.

Childbirth and infectious diseases were once the leading causes of death among women around the globe. That’s changed over the last three decades. Today, noncommunicable diseases (NCDs), once considered diseases of affluence, are, along with injuries, the leading causes of death and disability among women in developing and developed countries alike. Noncommunicable diseases affect women and children across the life-course: They are a critical issue for child and adolescent health, a threat to maternal and reproductive health, and a major driver of ill health for older women.

Described as a “slow, accounting for almost three-quarters of all deaths.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks